Amicus Therapeutics Inc (FRA:AM6)
€ 9.3 0.2 (2.2%) Market Cap: 2.82 Bil Enterprise Value: 3.01 Bil PE Ratio: 0 PB Ratio: 16.43 GF Score: 78/100

Q3 2024 Amicus Therapeutics Inc Earnings Call Transcript

Nov 06, 2024 / 01:30PM GMT
Release Date Price: €10.7 (+3.88%)
Operator

Good morning, ladies and gentlemen and welcome to the Amicus Therapeutics Inc third quarter, 2024 financial results conference call and webcast. At this time, all participants are in a listen-only mode later, we will conduct a question and answer session and instructions will follow at that time. As a reminder, this conference call is being recorded. I would now like to turn the conference over to your host, Mr Andrew Faughna, Vice President, Investor Relations. You may now begin.

Andrew Faughna Amicus Therapeutics Inc;Vice President
Investor Relations

Good morning. Thank you for joining our conference call to discuss amicus therapeutics. Third quarter, 2024 financial results and corporate highlights leading today's call. We have Bradley L. Campbell, President and Chief Executive Officerr, Sébastien Martel, Chief Business Officer, Dr Jeffrey P. Castelli, Chief Development Officer and Simon Harford, Chief Financial Officer. Joining for Q&A is Ellen S. Rosenberg, Chief Legal Officer. As referenced on slide 2.

We might make forward

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot